ZD 1839 “IRESSA” IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): ASSESSMENT OF TOLERABILITY AND THE CLINICAL BENEFIT


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles